Immune cell response, relative ‘heat’ of the tumor microenvironment, immune/inflammatory pathway activations, and genetic mutation profiles may predict the likelihood of benefit from immunotherapy in relation to MSLN expression, specifically in patients with MSS tumors. The gene discussed is MSLN; the disease is neoplasm.